Archive Issue Details

Abstract
Efgartigimod (efgartigimodalfa-fcab, Vyvgart™) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. It used specifically in generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. Efgartigimod binds to the FcRn and inhibits its interaction with IgG, thereby reducing IgG recycling and increasing degradation of IgG and pathological auto antibodies, with

Files
View PDF